The potentially $1 billion alliance centered around a flexible gene editing technology adds to a portfolio of cutting-edge ...

Still, the medications in the latest round of negotiations — which now includes “Part B” drugs given in doctors offices — ...

The development of a brain tumor in a study participant led regulators to suspend a Hurler syndrome therapy in early testing ...

Halozyme is paying as much as $400 million for a drug delivery specialist that could boost its growth prospects, one analyst ...

A drug Roche acquired in a multibillion-dollar deal could be as effective as Zepbound, but may struggle to stand out in a ...

Fresh data from multiple studies suggest the drug, which Sanofi has billed as a future blockbuster, could be cleared in the U ...

On a Monday conference call, Sarepta CEO Doug Ingram said new long-term data should help “rebalance the discussion” ...

In certain cases, regulators will now be open to clearing therapies based on their ability to eliminate tumor cells, a change ...

TRex Bio banked a Series B extension to advance its atopic dermatitis program, which is competing in a crowded field.

The “Great Healthcare Plan” is vague, but would send money directly to ACA enrollees and entrench the pricing deals the ...

The results build on evidence U.S. regulators found so compelling last year they proactively awarded J&J a new kind of drug ...

More than 3,000 prescriptions were written for Novo’s GLP-1 pill in its first week on the market. Elsewhere, Emergent reached ...